» Articles » PMID: 34249397

Regulatory Effect of Cannabidiol (CBD) on Decreased β-Catenin Expression in Alopecia Models by Testosterone and PMA Treatment in Dermal Papilla Cells

Overview
Date 2021 Jul 12
PMID 34249397
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The hair follicle is composed of more than 20 kinds of cells, and mesoderm derived dermal papilla cells and keratinocytes cooperatively contribute hair growth via Wnt/β-catenin signaling pathway. We are to investigate β-catenin expression and regulatory mechanism by CBD in alopecia hair tissues and dermal papilla cells.

Methods: We performed structural and anatomical analyses on alopecia patients derived hair tissues using microscopes. Pharmacological effect of CBD was evaluated by β-catenin expression using RT-PCR and immunostaining experiment.

Results: Morphological deformation and loss of cell numbers in hair shaft were observed in alopecia hair tissues. IHC experiment showed that loss of β-catenin expression was shown in inner shaft of the alopecia hair tissues, indicating that β-catenin expression is a key regulatory function during alopecia progression. Consistently, β-catenin expression was decreased in testosterone or PMA treated dermal papilla cells, suggesting that those treatments are referred as a model on molecular mechanism of alopecia using dermal papilla cells. RT-PCR and immunostaining experiments showed that β-catenin expression was decreased in RNA level, as well as decreased β-catenin protein might be resulted from ubiquitination. However, CBD treatment has no changes in gene expression including β-catenin, but the decreased β-catenin expression by testosterone or PMA was restored by CBD pretreatment, suggesting that potential regulatory effect on alopecia induction of testosterone and PMA.

Conclusion: CBD might have a modulating function on alopecia caused by hormonal or excess of signaling pathway, and be a promising application for on alopecia treatment.

Citing Articles

Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.

Luz-Veiga M, Mendes A, Tavares-Valente D, Amorim M, Conde A, Pintado M Int J Mol Sci. 2024; 25(22).

PMID: 39596290 PMC: 11595262. DOI: 10.3390/ijms252212224.


Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.

Ramer R, Hinz B Cells. 2022; 11(24).

PMID: 36552866 PMC: 9777118. DOI: 10.3390/cells11244102.

References
1.
Parker L, Mechoulam R, Schlievert C . Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport. 2002; 13(5):567-70. DOI: 10.1097/00001756-200204160-00006. View

2.
Ekanayake-Mudiyanselage S, Thiele J . [Sebaceous glands as transporters of vitamin E]. Hautarzt. 2006; 57(4):291-6. DOI: 10.1007/s00105-005-1090-7. View

3.
Seltzer E, Watters A, MacKenzie Jr D, Granat L, Zhang D . Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers (Basel). 2020; 12(11). PMC: 7693730. DOI: 10.3390/cancers12113203. View

4.
Rosenquist T, Martin G . Fibroblast growth factor signalling in the hair growth cycle: expression of the fibroblast growth factor receptor and ligand genes in the murine hair follicle. Dev Dyn. 1996; 205(4):379-86. DOI: 10.1002/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F. View

5.
Iino M, Ehama R, Nakazawa Y, Iwabuchi T, Ogo M, Tajima M . Adenosine stimulates fibroblast growth factor-7 gene expression via adenosine A2b receptor signaling in dermal papilla cells. J Invest Dermatol. 2007; 127(6):1318-25. DOI: 10.1038/sj.jid.5700728. View